Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776004 · ClinicalTrials.gov registry record · Phase 2
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
A Phase 2 study of Pneumonia, Bacterial, sponsored by Eagle Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT05776004 is a Phase 2 study of Pneumonia, Bacterial that is active but no longer recruiting, run by Eagle Pharmaceuticals. The registered enrollment target is 276 participants, below the 1,310-participant average among 7 other Pneumonia, Bacterial trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05776004, a Phase 2 study of Pneumonia, Bacterial, is active but no longer recruiting, sponsored by Eagle Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CAL02
Study Locations (20)
Other
- Hospital Misericordia Nuevo Siglo - Córdoba
- Hospital Central - Mendoza
- Clinique Universitaire Saint Luc - Brussels
- Clinique Saint Pierre - Ottignies
- Chu-Ucl-Namur - Yvoir
- Unidade de Pesquisa Clinica da Faculdade de Medicina de Botucatu - Botucatu
- Hospital do Servidor Publico Estadual - São Paulo
Buenos Aires
- Hospital Interzonal General de Agudo Dr Jose Pena - Bahía Blanca
- Hospital Italiano de Buenos Aires - Ciudad Autonoma de Buenos Aires
Alberta
- Foothills Hospital Medical Centre - Calgary
- Peter Lougheed Centre - Calgary
California
- UCSF Hospital - Fresno
Florida
- UF Health Shands Hospital - Gainesville
Illinois
- Northwestern Memorial Hospital - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Wake Forest Baptist Health Hospital - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2023-07-22 |
| Est. Completion | 2026-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05776004
The ClinicalTrials.gov registry entry for NCT05776004 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,310-participant average among 7 other Pneumonia, Bacterial trials with a reported enrollment target (79% lower). The listed sponsor is Eagle Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumonia, Bacterial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05776004 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Buenos Aires, Alberta.
Frequently Asked Questions
What is clinical trial NCT05776004 about?
NCT05776004 is a clinical study titled "Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia". This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
What is the current status of trial NCT05776004?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2023-07-22. Estimated completion is 2026-09-07.
What conditions does trial NCT05776004 study?
This clinical trial studies the following conditions: Pneumonia, Bacterial.
What interventions are being tested in trial NCT05776004?
The interventions under investigation include: Placebo (DRUG), CAL02 (DRUG).
Who is sponsoring clinical trial NCT05776004?
This trial is sponsored by Eagle Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05776004 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Nebraska, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia, Bacterial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
COMPLETED · Phase 2
-
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
COMPLETED · Phase 2
-
Discharge Stewardship in Children's Hospitals
ACTIVE NOT RECRUITING · NA
-
Pneumonia Direct Pilot
COMPLETED
-
Urease Breath Test for Rapid Characterization of Pneumonia
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.